April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Impact of Antiangiogenetic Therapy on Differences in Retinal Thickness Measurements Performed by Time- and Spectral Domain Optical Coherence Tomography in Age-Related Macular Degeneration
Author Affiliations & Notes
  • I. Golbaz
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • C. Ahlers
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • C. Schuetze
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • G. Stock
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • G. Mylonas
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • U. Schmidt-Erfurth
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Footnotes
    Commercial Relationships  I. Golbaz, None; C. Ahlers, None; C. Schuetze, None; G. Stock, None; G. Mylonas, None; U. Schmidt-Erfurth, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5256. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      I. Golbaz, C. Ahlers, C. Schuetze, G. Stock, G. Mylonas, U. Schmidt-Erfurth; Impact of Antiangiogenetic Therapy on Differences in Retinal Thickness Measurements Performed by Time- and Spectral Domain Optical Coherence Tomography in Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5256.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : It is well known that different optical coherence tomography (OCT) systems provide different retinal thickness (RT) measurements. However, it was anticipated that there is a systemic difference in RT measurements. It was the aim of this study to evaluate the impact of antiangiogenetic therapy on the differences in retinal thickness measurements performed with two different OCT systems from the same manufacturer.

Methods: : Data were obtained by two different OCT systems in a group of 20 Patients with neovascular age-related macular degeneration (nAMD) before and following three intravitreal treatments with Ranibizumab in monthly intervals. Imaging was performed using the time domain (TD) Stratus® and the spectral domain (SD) Cirrus® OCT system (both systems are manufactured by Carl Zeiss Meditec). Retinal Voulme (RV), central retinal thickness and central millimeter thickness analyses were carried out using the latest software available.

Results: : Mean RT and RV revealed to be significantly lower in conventional TD-OCT parameters than in SD-OCT parameters before and after treatment with Ranibizumab (p<0,002). Differences in all morphological parameters varied stronger in patients examined before than after treatment, demonstrating higher Standard Deviation (SD) previous to treatment. Most interestingly, the difference between TD- and SD-OCT retinal thickness measurements before and following antiangiogenetic therapy were highly significant (p < 0,01) and significantly lower than before the therapeutic intervention.

Keywords: imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • age-related macular degeneration • imaging/image analysis: clinical 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×